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ABSTRACT  
Oral fast dissolving midodrine hydrochloride films prepared by solvent casting method, PEG 400 was the selected plasticizers, incorporating 
superdisintegrants such as croscarmellose sodium (CCS) and sodium starch glycolate (SSG) to achieve the goal. Drug content, w eight variability, 
film thickness, disintegration time, endurance, percentage of moisture content, and in vitro dissolution tests were analyzed for the prepared 
films. In all formulations, the tensile strength value was found from 0.965±0.045 and 1.256±0.032 and the folding capacity was over 100. The 
assay values ranged from 97.98±0.25 to 99.89±0.36 percent for all formulations. The disintegration time was ranging betwee n 55±9 to 120±6 
sec, the minimum time for disintegration was found in formulation F5 (55±9). The prepared F5 formulation shows greater release of the drug 
(99.25±0.41 percent) within 15 min relative to other formulations. As the drug having low solubility, fast disintegration may leads to more drug 
availability for dissolution, resulting in faster absorption in systemic circulation increased systemic availability of drug leads to quick onset of 
action which is prerequisite for hypertension. 
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INTRODUCTION  
The rapidly dissolving dosage forms are referred by various 
names by researchers like quick disintegrating, orally 
disintegrating, mouth dissolve or melt in mouth dosage 
forms1,2,3. Rapidly dissolving or quick dissolving dosage 
forms have acquired great importance in the pharmaceutical 
industry due to their unique properties and advantages1,4. 
These dosage forms possess certain specific advantages like 
no need of water for disintegration, accurate dosing, rapid 
onset of action, ease of transportability, ease of handling, 
pleasant taste and improved patient compliance. United 
States Food and Drug Administration (USFDA) defined the 
fast dissolving oral thin films as a thin, flexible, non-friable 
polymeric film strip containing one or more 
dispersed/dissolved active pharmaceutical ingredients, 
which is intended to be placed on the tongue for rapid in 
vitro disintegration or dissolution in the saliva prior to 
swallowing for delivery into the gastrointestinal tract 5. They 
undergo disintegration in the salivary fluids of the oral cavity 
within a minute, where they release the active 
pharmaceutical ingredient. The major amount of the active 
pharmaceutical ingredient is swallowed orally with the 
saliva where subsequent absorption takes place in the 
gastrointestinal tract3,4. Midodrine Hydrochloride is an 
Antihypotensive/Vasopressor agent. Its chemical name is 2-
amino N-[2-(2,5-dimethoxyphenyl)-2-hydroxy-ethyl]-
acetamide. Melting Point is 200 to 203°C.pKa value is 7.8 
(0.3% aqueous solution). pH is 3.5 to 5.5(5% aqueous 
solution). It is also used in the treatment of Cirrhosis and 
Hepato renal syndrome. Marketed brands are Bramox, 
Gutron, Amatine6. The developed formulation was simple, 
easy to prepare and economical with great applicability and 
also giving faster in vitro drug dissolution rate as compared 
to the commercially available immediate release tablets. 
MATERIALS AND METHODS  
Materials 
Midodrine Hydrochloride was obtained as a gift sample from 
pharmaceutical company. HPMC was procured from 
Qualikems fine chem. Pvt Ltd Vadodhara. PEG400, sodium 
starch glycolate, croscarmellose sodium was obtained from 
S.D fine chemicals limited, Mumbai. Citric acid, ethanol was 
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obtained from Loba Chemical Pvt Ltd (Mumbai, India). 
Hydrochloric acid, KH2PO4, NaOH was obtained from S. D. 
Fine Chem. Ltd., Mumbai. All other chemical were purchased 
from Hi Media, Mumbai. Double distilled water was prepared 
freshly and used whenever required. All the chemicals used 
in this work were of analytical grade. 
Formulation development of oral film  
Solvent casting technique 
Drug Midodrine hydrochloride was manufactured using 
solvent casting method, containing fast dissolving films. The 
optimized quantity of HPMC was dissolved in 5ml of water 
and continuously stirring for 1 hour, the optimized quantity 
of Plasticizer and drug was dissolved in 95 percent ethanol 
and then applied to the polymer solution, the optimized 
quantity of drug was dissolved in 2ml of water and placed on 
sonication for proper dispersion. Polymeric solution was 
stirred for 30 min using magnetic stirrer and was kept in 
undisturbed condition till the entrapped air bubbles were 
removed. The aqueous solution was casted in a glass moulds 
having 2.5 x 2.5 cm x 12 films area and was dried at 
controlled room temperature (25°-30°C, 45 %RH) as well as 
at increased temperature (microwave oven). The film took 
approximately 48 hr to dry at controlled room temperature. 
The dried film was carefully removed from the glass plates 
and was cut into size required for testing. The films were 
stored in air tight plastic bags till further use. The 
compositions of the formulations were shown in table 1 and 
prepared formulation shown in figure 1&2. 
 
Table 1: Selection and Optimization of Film Forming Agents 
Name of ingredients 
(mg) 
(mg for 12 strips) 
F1 F2 F3 F4 F5 F6 
API 60 60 60 60 60 60 
HPMC 250 300 350 400 450 500 
Glycerin - - - - - - 
PEG-400 100 100 100 100 100 100 
SSG 100 200 300 - - - 
CCS - - - 100 200 300 
Aspartame 5 5 5 5 5 5 
Citric acid 50 50 50 50 50 50 
DM water  qs to (ml) - - - - - - 
 
Dose calculations 
 Width of the plate = 5cm 
 Length of the plate = 12cm 
 No. of 2.5 x 2.5 cm2 films present whole plate = 12 
 Each film contains 20mg of drug. 
 12 no. of films contains mg of drug? = 5×12 = 60mg 
 The amount of drug added in each plate was approximately equal to 60mg. 
 
 
Figure 1: Preperation of fast dissolving oral films  
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Figure 2: Prepared fast dissolving oral film 
Evaluation 
The formulations were evaluated by the following tests7-10. 
Thickness 
Randomly 10 films were selected and thickness was 
measured using vernier calliper at three different places. 
Weight variation  
For each formulation, three randomly selected patches were 
used. For weight variation test, 10 films from each batch 
were weighed individually by digital electronic balance and 
the average weight was calculated. 
Folding endurance 
This was determined by repeatedly folding one film at the 
same place until it broke. The number of times the film could 
be folded at the same place without breaking cracking gave 
the value of folding endurance.  
Percentage of moisture content 
The films were weighed individually and kept in desiccators 
containing activated silica at room temperature for 24 hrs. 
Individual films were weighed repeatedly until they showed 
a constant weight. The percentage of moisture content was 
calculated as the difference between initial and final weight 
with respect to final weight.  
Drug content analysis 
The patches (n = 3) of specified area were taken into a 10 ml 
volumetric flask and dissolved in methanol and volume was 
made up with 10 ml methanol. Subsequent dilutions were 
made and analyzed by UV spectrophotometer at 272nm.  
Disintegrating time 
The most important criteria of present work are to that 
dosage form should be dissolved within few seconds. The 
incorporation of super disintegrating agent to minimizes the 
disintegrating time. Three super disintegrating agent were 
selected for this work. The film of (2.5*2.5cm2) size (unit 
dose) was placed on a petridish containing 10 ml of distilled 
water. The time required for the film to break was noted as 
cursive in vitro disintegration time Figure 3. 
 
 
Figure 3: Determination of disintegrating time 
 
In vitro dissolution study  
The in vitro dissolution test was performed using the 
USPXXX dissolution apparatus II (Paddle with sinker). The 
dissolution studies were carried out at 37±0.5°C; with 
stirring speed of 50 rpm in 900 ml phosphate buffer (pH 
6.8). Film size required for dose delivery (2.5×2.5 cm2) was 
used. Five ml aliquot of dissolution media was collected at 
time intervals of 1, 2, 5, 10 and 15 minutes and replaced 
with equal volumes of phosphate buffer (pH 6.8). The 
collected samples were filtered through 0.45 μm membrane 
filter and the concentration of the dissolved Midodrine 
hydrochloride was determined using UV-Visible 
spectrophotometer at 272 nm. The results were presented 
as an average of three such concentrations. 
RESULTS AND DISCUSSION 
The general appearance, assay, weight variation and 
thickness of all the films were within acceptable limits table 
2. The results for tensile strength, folding endurance, 
disintegrating time and % of moisture were shown in table 
3. Tensile strength value of found between 0.965±0.045 to 
1.256±0.032, and folding endurance was more than 100 in 
all formulations. The assay values of all the formulations 
were ranging from 97.98±0.25 to 99.89±0.36 %. The 
disintegration time was ranging between 55±9 to 120±6 sec, 
The Minimum disintegration time was found in formulation 
F5 (55±9). The optimized formulation F5 shows better drug 
release (99.25±0.41%) compared to other formulation 
within 15 min (Table 4). When the regression coefficient 
values of were compared, it was observed that ‘r’ values of 
first order was maximum i.e. 0.963 hence indicating drug 
release from formulations was found to follow zero order 
first order kinetics. The kinetic data of optimized 
formulation F5 was given in table 5. It was fallow first order 
drug release kinetics. 
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Table 2: Result of thickness, weight variation and % assay 
Formulation code Thickness in µm* Weight mg* % Assay* 
F1 85±5 132±4 98.85±0.65 
F2 89±6 135±6 97.78±0.74 
F3 94±8 146±8 96.65±0.52 
F4 98±9 155±6 98.12±0.63 
F5 102±12 163±8 99.56±0.14 
F6 105±10 173±7 96.56±0.23 
  *Average of three determinations (n=3) 
Table 3: Result of disintegrating time, tensile strength &% of moisture content 
Formulation 
code 
Disintegrating* time 
(Sec.) 
Tensile strength*  in  
kg/cm2 
Percentage of Moisture 
Content* 
F1 120±6 0.965±0.045 1.25±0.36 
F2 110±8 0.989±0.068 1.69±0.50 
F3 89±7 0.988±0.095 1.78±0.25 
F4 86±5 1.112±0.075 1.85±0.32 
F5 55±9 1.256±0.032 0.98±0.14 
F6 82±8 1.225±0.074 1.12±0.25 
  *Average of three determination (n=3) 
 
Table 4: Results of In-Vitro release study of optimized 
formulation F5 
S. No. Time (Min.) % CDR 
1. 1 33.45±0.89 
2. 2 49.65±0.65 
3. 5 65.62±0.25 
4. 10 88.45±0.36 
5. 15 99.25±0.41 
 
Table 5: Kinetics data of optimized formulation F5 
Formulation Regration 
Coefficient 
Zero order First 
order 
F5 r2 0.963 0.943 
 
CONCLUSION 
This is fast disintegrating oral film hence on the laboratory 
scale solvent casting technique was adopted for formulation 
of films. Different formulations (F1-F6) were prepared using 
varying amount of SSG and CCS. The prepared formulations 
were evaluated for thickness, weight uniformity, folding 
endurance, percentage of moisture content, drug content 
analysis, disintegrating time and in vitro dissolution study. 
Finally, it is concluded that the drug release from the fast 
dissolving film was increased by using the increased 
concentration of Superdisintegrant, thus assisting in faster 
disintegration in the buccal cavity. As the drug having low 
solubility, fast disintegration may leads to more drug 
availability for dissolution, resulting in faster absorption in 
systemic circulation increased systemic availability of drug 
may leads to quick onset of action which is prerequisite for 
hypertension. 
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